Monday, October 1, 2007

Raloxifene (Evista) Approved for Lowering Breast Cancer Risk in Postmenopausal Women

The FDA has approved Raloxifene to be used in two groups of women, namely those with osteoporosis and those at high risk of having breast cancer. This drug is like Tamoxifen that is currently used as prophylaxis in women with breast cancer. However, unlike Tamoxifen, Raloxifene does not cause cancer of the uterus. Both of them can cause hot flashes and clots in the veins. Unlike drugs like Fosamax or Actonel, Raloxifene does not prevent hip fractures. This is a boon to women with a history of osteoporosis in their spine and with a family history of breast cancer.